Patents by Inventor Hermann Lubbert

Hermann Lubbert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HTreceptor antagonist
    Patent number: 7511064
    Abstract: The present invention relates to derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and pharmaceutically acceptable salts thereof, use of these compounds as a medicament and for the manufacture of a medicament for treatment of a disease state which can be alleviated by treatment with a 5-HT2B antagonist.
    Type: Grant
    Filed: April 19, 2006
    Date of Patent: March 31, 2009
    Assignee: Biofrontera Bioscience GmbH
    Inventors: Hermann Lubbert, Christoph Ullmer, Emile Bellott, Mark Froimowitz, Douglas Gordon
  • DERIVATIVES OF 4-(THIO-OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST
    Publication number: 20060183905
    Abstract: The present invention relates to derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and pharmaceutically acceptable salts thereof, use of these compounds as a medicament and for the manufacture of a medicament for treatment of a disease state which can be alleviated by treatment with a 5-HT2B antagonist.
    Type: Application
    Filed: April 19, 2006
    Publication date: August 17, 2006
    Applicant: BIOFRONTERA BIOSCIENCE GmbH
    Inventors: Hermann Lubbert, Christoph Ullmer, Emile Bellott, Mark Froimowitz, Douglas Gordon
  • Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HTreceptor antagonist
    Patent number: 7060711
    Abstract: The present invention relates to derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and pharmaceutically acceptable salts thereof, use of these compounds as a medicament and for the manufacture of a medicament for treatment of a disease state which can be alleviated by treatment with a 5-HT2B antagonist.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: June 13, 2006
    Assignee: Biofrontera Bioscience GmbH
    Inventors: Hermann Lubbert, Christoph Ullmer, Emile Bellott, Mark Froimowitz, Douglas Gordon
  • Cathepsin Y for the development of a medicament for the treatment of stroke
    Publication number: 20030232740
    Abstract: The present invention relates to the use of a polynucleotide sequence en-coding Cathepsin Y or a amino acid sequence of Cathepsin Y protein for the characterization or identification of therapeutic agents for stroke, the use of such sequences for the development of a medicament, and agents useful as medicaments for the treatment of stroke.
    Type: Application
    Filed: March 19, 2003
    Publication date: December 18, 2003
    Inventors: Hermann Lubbert, Stefan Zwilling, Peter Engels
  • Multiple genes relevant for the characterization, diagnosis, and manipulation of stroke
    Publication number: 20030219807
    Abstract: The present invention relates to the use of differentially expressed polynucleotide sequences or polypeptides for the characterization of stroke or progression thereof or progression of neurodegenerative processes as consequence thereof, a method for characterizing stroke, a method for identifying therapeutic agents for stroke and the use of such sequences for the development of a medicament.
    Type: Application
    Filed: March 19, 2003
    Publication date: November 27, 2003
    Inventors: Hermann Lubbert, Peter Engels, Stefan Zwilling
  • Multiple genes relevant for the characterization, diagnosis, and manipulation of neuropathic pain
    Publication number: 20030216341
    Abstract: The present invention relates to the use of differentially expressed polynucleotide sequences or polypeptides for the characterization of pain status or progression, a method for characterizing pain, a method for identifying therapeutic agents for pain and the use of such sequences for the development of a medicament.
    Type: Application
    Filed: February 14, 2003
    Publication date: November 20, 2003
    Inventors: Hermann Lubbert, Peter Engels, Beate Schmitz
  • Cathepsin Y for the development of a medicament for the treatment of pain
    Publication number: 20030212003
    Abstract: The present invention relates to the use of a polynucleotide sequence encoding Cathepsin Y or a amino acid sequence of Cathepsin Y protein for the characterization or identification of therapeutic agents for pain, the use of such sequences for the development of a medicament, and agents useful as medicaments for the treatment of pain.
    Type: Application
    Filed: February 14, 2003
    Publication date: November 13, 2003
    Inventors: Hermann Lubbert, Peter Engels, Beate Schmitz
  • Derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist
    Publication number: 20030166672
    Abstract: The present invention relates to derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and pharmaceutically acceptable salts thereof, use of these compounds as a medicament and for the manufacture of a medicament for treatment of a disease state which can be alleviated by treatment with a 5-HT2B antagonist.
    Type: Application
    Filed: October 25, 2002
    Publication date: September 4, 2003
    Inventors: Hermann Lubbert, Christoph Ullmer, Emile Bellott, Mark Froimowitz, Douglas Gordon
  • 1-Methyl-4- (3-ethoxy-9H-thioxanthene-9-ylidene) -piperidine and its use as 5-HT2B/H1 receptor antagonist
    Publication number: 20030022920
    Abstract: The present invention relates to 1-methyl-4-(3-ethoxy-9H-thioxanthene-9-ylidene)-piperidine and pharmaceutically acceptable salts thereof, use of 1-methyl-4-(3-ethoxy-9H-thioxanthene-9-ylidene)-piperidine as a medicament and for the manufacture of a medicament for treatment of a disease state which is alleviable by treatment with a 5-HT2B or H1 o or 5-HT2B/H1 receptor antagonists.
    Type: Application
    Filed: May 24, 2002
    Publication date: January 30, 2003
    Inventors: Christoph Ullmer, Hermann Lubbert, Mark Froimowitz, Emile Bellott, Douglas Gordon
  • LED panel for a photodynamic therapy lamp
    Patent number: D1021120
    Type: Grant
    Filed: October 19, 2021
    Date of Patent: April 2, 2024
    Assignee: Biofrontera Pharma GmbH
    Inventors: Markus Osterloh, Ben Novak, Hermann Lubbert
  • Photodynamic therapy lamp head
    Patent number: D1052103
    Type: Grant
    Filed: October 18, 2022
    Date of Patent: November 19, 2024
    Assignee: BIOFRONTERA PHARMA GMBH
    Inventors: Markus Osterloh, Ben Novak, Hermann Lubbert
  • Photodynamic therapy lamp
    Patent number: D1067446
    Type: Grant
    Filed: October 18, 2022
    Date of Patent: March 18, 2025
    Assignee: BIOFRONTERA PHARMA GMBH
    Inventors: Markus Osterloh, Ben Novak, Hermann Lubbert